Topoisomerase inhibitor coralyne photosensitizes DNA, leading to elicitation of Chk2-dependent S-phase checkpoint and p53-independent apoptosis in cancer cells

Antioxidants and Redox Signaling

Volumn 12, Issue 8, 2010, Pages 945-960

  Patro, Birija Sankar ^a   Maity, Biswanath ^a   Chattopadhyay, Subrata ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CHECKPOINT KINASE 2; CORALYNE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ULTRAVIOLET A RADIATION;

ANIMALS; APOPTOSIS; BERBERINE ALKALOIDS; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PHOTOSENSITIZING AGENTS; PROTEIN-SERINE-THREONINE KINASES; S PHASE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ULTRAVIOLET RAYS;

EID: 77949601774     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2508     Document Type: Article

References (52)

1. Aas T, Borreson A-L, Geisler S, Smith-Sorenson B, Johnsen H, Varhaug JE, Akslen LA, and Lonning P. Specific P53 mutations are associated with de novo resistance to doxo-rubicin in breast cancer patients. Nat Med 2: 811-814, 1996.
2. Amorino GP, Mikkelsen RB, Valerie K, and Schmidt-Ullrich RK. Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair, leading to increased cellular radiosensitivity. J Biol Chem 278: 29394-29399, 2003.
3. Antonsson B and Martinou JC. The Bcl-2 protein family. Exp Cell Res 256: 50-57, 2000.
4. Bergh J, Norberg T, Slogren S, Lindgren A, and Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995.
5. Bohne C, Faulhaber K, Giese B, Hafner A, Hofmann A, Ihemels H, Pera S, Shneider F, and Sheepwash M. Studies on the mechanism of the photo-induced DNA damage in the presence of acridizinium salts: involvement of singlet oxygen and an unusual source for hydroxyl radicals. J Am Chem Soc 127: 76-85, 2005.
6. 2 delay potentiates cell death by apoptosis and=or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 3: 1371-1381, 1997.
7. Brezova V, Voranova D, and Kostalova D. Oxygen activation by photoexcited protoberberinium alkaloids from Ma-honia aquifolium. Phytother Res 18: 640-644, 2004.
8. Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, and Baskaran R. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet 33: 80-84, 2002.
9. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, and Sar-karia JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60: 2108-2112, 2000.
10. Caffieri S, Di Lisa F, Bolesani F, Facco M, Semenzato G, Dall'Acqua F, and Canton M. The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy. Blood 109: 4988-4994, 2007.
11. Covey JM, Jaxel C, Kohn KW, and Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49: 5016-5022, 1989.
12. El-Deiry WS. The role of p53 in chemosensitivity and ra-diosensitivity. Oncogene 22: 7486-7495, 2003.
13. Evan GI and Vousden KH. Proliferation, cell cycle and ap-optosis in cancer. Nature 411: 342-343, 2001.
14. Falck J, Mailand N, Syljuasen RG, Bartek J, and Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410: 842-847, 2001.
15. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie E, and Liu LF. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56: 2795-2800, 1996.
16. Goh H, Yao J, and Smith, D. p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221, 1995.
17. Hengartner MO. The biochemistry of apoptosis. Nature 407: 770-776, 2000.
18. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, and Mak TW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824-1827, 2000.
19. 2=M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963, 2001.
20. Hsu HF, Houng JY, Kuo CF, Tsao N, and Wu. YC. Glosso-gin, a novel phenylpropanoid from Glossogyne tenuifolia, induced apoptosis in A549 lung cancer cells. Food Chem Toxicol 46: 3785-3791, 2008.
21. Ihmels H, Faulhaber K, Sturm C, Bringman G, Gabellini N, Vedaldi D, and Viola G. Acridizinium salts as a novel class of DNA-binding and site-selective DNA-photodamaging chromophores. Photochem Photobiol 74: 505-511, 2001.
22. Ihmels H and Salbach A. Efficient photoinduced DNA damage by coralyne. Photochem Photobiol 82: 1572-1576, 2006.
23. Kastan MB and Bartek J. Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004.
24. Kastan MB and Lim D. The many substrates and functions of ATM. Nat Rev 1: 179-186, 2000.
25. Khanna KK and Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254, 2001.
26. Liu L. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
27. Lowe SW. Cancer therapy and p53 Curr Opin Oncol 7: 547-553, 1995.
28. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, and Klein-SzantoA, Dionne C,and RuggeriB. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382, 2003.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
30. Painter RB and Young BR. Radiosensitivity in ataxia-telangiectasia: a new explanation. Proc Natl Acad Sci USA 77: 7315-7317, 1980.
31. Pilch DS, Yu C, Markhey D, La Voie EJ, Srinivasan AR, Olson WK, Sauers RR, Breslauer KJ, Geacintov NE, and Liu LF. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs. Biochemistry 36: 12542-12553, 1997.
32. 2 delay. Cancer Res 55: 1643-1648, 1995.
33. Reelfs O, Xu YZ, Massey A, Karran P, and Storey A. Thio-thymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status. Mol Cancer Ther 6: 2487-2495, 2007.
34. Rojas E, Lopez MC, and Valverde M. Single cell gel elec-trophoresis assay: methodology and applications. J Chro-matogr B 722: 225-254, 1999.
35. Schneider E, Hsiang YH, and Liu LF. DNA topoisomer-ases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990.
36. Seiler JA, Conti C, Syed A, Aladjem MI, and Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and-DNA fiber analyses. Mol Cel Biol 27: 5806-5818, 2007.
37. Shankaranarayanan P and Nigam S. IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15- hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor g transcription factor. J Immunol 170: 887-894, 2003.
38. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, and Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57: 4029-4035, 1997.
39. Siddik Z. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
40. Sørensen CS, Syljuasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK, Zhou B, Bartek J, and Lukas J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3: 247-258, 2003.
41. Soussi T, Dehouche K, and Beroud, C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15: 105-113, 2000.
42. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, and Taylor AM. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99: 577-587, 1999.
43. Urist M, Tanaka T, Poyurovsky MV, and Prives C. Chk1 and Chk2 p73 induction after DNA damage is regulated by checkpoint kinases. Genes Dev 18: 3041-3054, 2004.
44. Virag L and Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429, 2002.
45. Viola G, Bressanini M, Gabellini N, Vedaldi D, Dall'Acqua F, and Ihmels H. Naphthoquinolizinium derivatives as a novel platform for DNA-binding and DNA-photodamaging chro-mophores. Photochem Photobiol Sci 1: 882-889, 2002.
46. Viola G, Dall'Acqua F, Gabellini N, Moro S, Vedaldi D, and Ihmels H. Indolo[2,3-b]-quinolizinium bromide: an efficient intercalator with DNA-photodamaging properties. Chem Biochem 3: 550-558, 2002.
47. Vousden KH and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002
48. Weiss RH. p21Waf1=Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429, 2003.
49. 2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 505: 7-12, 2001.
50. Zee-Cheng KY and Cheng CC. Solubilization and stabilization of the cytotoxic agent coralyne. J Med Chem 19: 882-886, 1976.
51. Zee-Cheng KY, Paull KD, and Cheng CC. Experimental antileukemic agents: coralyne, analogs, and related compounds. J Med Chem 17: 347-351, 1974.
52. Zijlstra JG, de-Jong S, de Vries EG, and Mulder NH. To-poisomerases, new targets in cancer chemotherapy. Med-Oncol Tumor Pharmacother 7: 11-18, 1990